Brilliant Margalin, S. P. Edijanto, Paulus B. Notopuro


Fibrin glue is a useful biological product to stop bleeding, adhesive tissue and accelerate wound healing. Preparation of Fibrin Glue requires fibrinogen and thrombin components. The routine cryoprecipitation method performed at the Blood Bank can be used to improve the quality of the fibrinogen component. The Freeze Drying process can increase the retention time of plasma products at room temperature. Yield Fibrinogen and Tensile Strength is a quantitative and qualitative parameter of preparation quality of fibrin glue. This study focused on finding differences between Tensile Strength and Yield Fibrinogen on fibrin glue preparative by cryoprecipitate with and without freeze drying methods.

This study is in vitro laboratory experiments design by comparing the Yield Fibrinogen and Tensile Strength of fibrin glue preparation from cryoprecipitic plasma with and without freeze dried process. The results were analyzed comparatively using paired T test.

The plasma fibrinogen content of the sample was 237.66 ± 67.10 mg / dL. The fibrinogen content of the cryoprecipitate component without freeze drying process was 327.74 ± 103.42 mg / dL with a yield fibrinogen of 1.38 ± 0.25. The fibrinogen content of the cryoprecipitate component with freeze drying process was 251.20 ± 103.91 mg / dL with yield fibrinogen 1.04 ± 0.25. Tensile strength of fibrin glue from cryoprecipitate without freeze drying process was found to average 0.52 ± 0.18. Tensile strength of fibrin glue from cryoprecipitate with freeze drying process was found to average 0.33 ± 0.12. There was a significant difference between yield fibrinogen and tensile strength of fibrin glue preparation of cryoprecipitation method with and without freeze dried process.

There is a significant difference on yields fibrinogen and tensile strength in the preparation of fibrin glue by the freeze drying process which is probably due to changes in the structure and function of fibrinogen proteins.


Cryopresipitate, Freeze Drying, Fibrin Glue,Yield Fibrinogen, Tensile Strength


Reiss RF., Oz MC., Autologous Fibrin Glue : Production and Clinical Use., Tranfusion Medicine Review, April 1996; X (2): p86 – 92.

Noori A., Ashrafi SJ., Ghaemi RV., Zaremi AH., Webster TJ., A Review of Fibrin and Fibrin Composites For Bone Tissue Engineering., International Journal of Nanomedicine, 2017;12 : 4937 – 4961.

Hilyer, Silberstein, Ness, Andersen, Roback. Blood Banking and Tranfusion Medicine. Basic Principles and Practice. 2nd edition. Philladelphia, Elseveir. 2007; p. 270 – 277

Ness PM., Perkins HA., Fibrinogen in Cryoprecipitate and Its Relationship to Factor VIII (AHF) Levels. Tranfusion, January – February 1980; 20 (1): 93-6.

CavichioloJB.,BuschleM.,CarvalhoB., Comparison of Fibrin Adhesive Prepared by 3Different Method.Int.Arch., Otorhinolaryngol, 2013;17(1):62-65.

Inaba K., Freeze-Dried Plasma., The Journal of Trauma,Injury, Infection and Critical Care., May 2011;70(5) :.57-58

Kjaergard HK., Weis-Fogh US. Important Factors influencing the Strength of Autologous Fibrin Glue; The Fibrin Concentration and Reaction Time – Comparison of Strength With Commercial Fibrin Glue. Ear Surg Res 1994; 26: 273 – 276.

Piedras J., Sanchez Montero PE., Harrera FM., Cordova MS., Sanchez Medal L., Effect of Plasma Freezing Temperature, Anticoagulant and Time of Storage on Factor VIII:C activity in Cryoprecipitate., Arch Med Res., 1993;24(1):23-26

Cao W., Krishnan S., Ricci MS., L.Y. Shih, D. Liu, J.H. Gu., Rational Design of Lyophilized High Concentration Protein Formulations-Mitigating The Challenge of Slow Reconstitution With Multidisciplinary Strategies., European Journal of Pharmaceutics and Biopharmaceutics 2013; 85: 287 – 293.

Marx G., Blankenfeld A. Kinetic and Mechanical Parameters of Pure and Cryoprecipitate Fibrin., Blood Coagul Fibrinolysis., Feb 1993; 4(1): 73-78.

Wahl V., Saurugger E., Khinast J., Laggner P. Specific Surface, Crystallinity and Dissolution of Lyophillized Fibrinogen. A Study by Combined and Wide Angle X-Ray Scattering (SWAXS). European Journal of Pharmaceutics and Biopharmaceutics. January 2015; 89 :374 - 382



  • There are currently no refbacks.